Table 1 Main characteristics of all included studies
From: Prognostic impact of tumor length in esophageal Cancer: a systematic review and Meta-analysis
Author | Publication year | Patient source | No. of patients | Age (years) (median and range) | Follow-up (months) (median and range) | Treatment | LN metastasis (% of total) | histology | Tumor location | TNM stage | III/IV (% of total) | Cut-off value (cm) | Survival analysis | HR reported | NOS | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upper | Middle | Lower | |||||||||||||||
Tachibana, M. | 1999 | Japan | 65 | 65 | NR | Surg2 | 30.77 | SCC | 6 | 59 | T1–2N± | NR | 4 | OS | MV | 7 | |
Shimada, H. | 2004 | Japan | 374 | 65 | NR | Surg2 | 65.78 | SCC | 98 | 276 | I-IV | 77.0 | 5 | OS | MV | 6 | |
Barbour, A. P. | 2008 | Australia | 131 | 61(30–78) | 61 | Surg3 | 51.15 | SCC, AC | 4 | 28 | 85 | 0-III | 32.8 | 6 | DSS | MV | 8 |
Yendamuri, S. | 2009 | US | 209 | 64 (33–84) | NR | Surg2 | 45.45 | SCC, AC | 3 | 27 | 179 | I-III | 34.9 | 3 | OS | UV/MV | 7 |
Shitara, K. | 2010 | Japan | 363 | 63 | 67.2 (25.2–94.8) | Surg1 | NR | SCC | NR | I-IV | 56.2 | 5 | OS | UV/MV | 7 | ||
Heijl, M. V. | 2010 | The Netherlands | 199 | 64 (35–78) | 60+ | Surg2 | 72.36 | SCC, AC | NR | NR | NR | 4 | OS/DFS | UV/MV | 8 | ||
Gaur, P. | 2011 | US | 164 | 65 (26–84) | NR | Surg2 | 14.63 | AC | 0 | 8 | 156 | NR | NR | 2 | OS | UV/MV | 8 |
Lu, C. L. | 2011 | China | 127 | 59 (39–77) | NR | Surg2 | 32.28 | SCC | NR | I-III | 30.7 | 2 | OS/DFS | MV (RR) | 7 | ||
Wang, B. Y. | 2011 | China | 582 | 65.4 (30–88) | 31.9 | Surg2 | 54.64 | SCC | 77 | 340 | 165 | T1-4N0–3 | NR | 3 | OS | MV | 7 |
Yamamoto, S. | 2011 | Japan | 170 | 64 | NR | Surg1 | NR | SCC | 18 | 107 | 45 | I | NR | 5 | OS | MV | 6 |
Song, Z. B. | 2012 | China | 201 | 59 (31–78) | 52 (30–136) | Surg | NR | SCC | 12 | 102 | 87 | T1-2 | NR | 3 | OS | MV | 7 |
Chen, J. | 2012 | China | 945 | NR | NR | Surg2 | 100 | SCC | 146 | 712 | 87 | T1-4N+ | NR | 5 | OS | UV/MV | 7 |
Feng, J. F. | 2013 | China | 132 | 73.6 ± 2.6 | NR | Surg2 | 56.11 | SCC | 6 | 55 | 71 | T1-4N0–3 | NR | 4 | OS | UV/MV | 6 |
Matsumoto, S. | 2013 | Japan | 32 | 63 | NR | Surg2 | 42.86 | SCC | 3 | 20 | 6 | I-III | 71.9 | 6 | OS | MV | 7 |
Zeybek, A. | 2013 | Turkey | 116 | 60.0 (33–75) | 39.7 | Surg2 | 65.52 | SCC, AC | 10 | 36 | 70 | II-III | 64.7 | 3 | DFS | MV | 6 |
Chen, L. J. | 2014 | China | 103 | 58 | NR | Surg2 | 47.57 | SCC | NR | I-IV | 33.0 | 3.5 | OS | UV/MV | 7 | ||
Shridhar, R. | 2014 | US | 154 | 65 | NR | Surg1 | 84.42 | AC | 0 | 5 | 80 | I-IV | 68.8 | 5 | OS | MV | 6 |
Freilich, J. | 2015 | US | 232 | 64.4 ± 11.3 | 25.9 (2.5–124.2) | Surg1 | 83.19 | SCC, AC | 8 | 17 | 118 | I-IV | 72.8 | 5 | OS | MV | 7 |
Hulshoff, J. B. | 2015 | US | 105 | 64 (57–69) | 29 (15.–56.0) | Surg1 | 73.33 | SCC, AC | 0 | 12 | 49 | NR | NR | 5 | DFS | UV/MV | 6 |
Ma, M. Q. | 2015 | China | 362 | 54.5 | 84 (6–144) | Surg2 | 12.18 | SCC | 28 | 243 | 100 | I-III | 25.1 | 4 | OS | MV (RR) | 8 |
Miao, L. S. | 2015 | China | 1342 | 59.5 ± 7.9 | 30 | Surg2 | 45.98 | SCC, AC | NR | I-IV | 41.1 | 4 | OS | UV/MV | 7 | ||
Hirahara, N. | 2016 | Japan | 147 | 65.7 | NR | Surg1 | 59.86 | SCC | 8 | 65 | 52 | I-III | 37.4 | 3 | CSS | UV/MV | 7 |
Hwang, J. Y. | 2016 | China | 294 | 55 | 20.4 | Surg2 | 58.84 | SCC | 51 | 114 | 129 | I-IV | 49.3 | 3.2 | OS | UV/MV | 7 |
Jia, W. | 2016 | China | 83 | NR | NR | Surg2 | 56.63 | SCC | 8 | 44 | 31 | I-III | 43.4 | 5 | OS/DFS | MV | 6 |
Ma, Q. L. | 2016 | China | 725 | 58 (32–80) | NR | Surg2 | 46.48 | SCC | NR | I-III | 38.2 | 5 | OS | UV/MV | 7 | ||
Sakanaka | 2016 | Japan | 144 | 67 (41–85) | 48 (13–88) | CRT | 74.31 | SCC | 33 | 79 | 32 | I-IV | 63.9 | 4 | OS | MV | 7 |
Valmasoni, M. | 2016 | Italy | 357 | 62 ± 9.3 | NR | Surg2 | 50.98 | SCC | 90 | 147 | 120 | I-III | 47.6 | 3 | OS | MV | 7 |
Valmasoni, M. | 2016 | Italy | 305 | 63 ± 11.2 | NR | Surg2 | 66.23 | AC | 0 | 6 | 299 | I-III | 58.4 | 3 | OS | MV | 7 |
Wu, J. | 2016 | China | 1435 | 58.3 | 24 (1–128) | Surg2 | 53.24 | SCC | 33 | 691 | 711 | T1-4N0–3M0–1 | NR | 4 | OS | UV/MV | 7 |
Duan, J. | 2016 | China | 328 | 61 | 44.9 (3.4–107.6) | Surg2 | 42.4 | SCC | 24 | 202 | 102 | I-III | 57.6 | 4.2 | OS/DFS | UV/MV | 8 |
Gao, S. H. | 2016 | China | 126 | NR | NR | Surg1 | 85 | SCC | NR | I-III | 54.8 | 4 | OS/DFS | MV | 6 | ||
Li, S. P. | 2016 | China | 100 | 59.2 ± 10.3 | NR | Surg1 | 55 | SCC | 12 | 41 | 37 | I-III | 54.0 | 4 | OS/DFS | MV | 6 |
Tian, R. | 2016 | China | 442 | 60 (20–88) | NR | Surg2 | 47.5 | SCC | 39 | 277 | 126 | I-III | 43.7 | 5 | OS/DFS | UV/MV | 7 |
Xi, M. | 2017 | US | 496 | 67 (20–92) | 24.2 (2.8–155.9) | CRT | 70.97 | SCC, AC | 138 | 358 | I-III | 67.9 | 5 | PFS | MV | 7 | |
Zeng, Y. | 2017 | US | 1242 | NR | NR | Surg | NR | SCC, AC | 39 | 136 | 913 | NR | NR | 1.5 | OS/CSS | MV | 7 |
Li, J. | 2017 | China | 294 | 58 (38–70) | 26 | Surg2 | 67.3 | SCC | 6 | 139 | 149 | T1-4N± | NR | 5 | OS | MV | 7 |
Yang, Y. S. | 2017 | China | 508 | 59 | 37.5 (1–105) | Surg2 | 40.9 | SCC | 78 | 260 | 170 | T1-4N± | NR | 4 | OS | UV/MV | 7 |
Zhang, X. W. | 2017 | China | 498 | 59 (38–81) | 47.2 (6.–64.5) | Surg2 | 41 | SCC | NR | T1-4N± | NR | 3 | OS | UV/MV | 7 | ||
Bai, G. | 2018 | China | 80 | 54.7 ± 12.6 | 28 (9–62) | Surg2 | 52.5 | SCC | 24 | 36 | 20 | T1-4N± | NR | 5 | OS/DFS | MV | 6 |
Cheng, Y. F. | 2018 | China | 14,394 | NR | NR | Surg1 | 73.5 | SCC | 2897 | 5028 | 3213 | 0-IV | 71.5 | 5 | OS | MV | 6 |
Xu, H. Y. | 2018 | China | 751 | 65 | 56.6 (25.2–112.5) | CRT | 78.96 | SCC + Others | 157 | 420 | 128 | T1-4N0–3 | NR | 5 | PFS | UV/MV | 7 |
Gu, L. | 2019 | China | 116 | NR | NR | Surg1 | 85.34 | SCC | NR | I-IV | 55.2 | 5 | OS | UV/MV | 6 | ||